Targeting Sirtuin-1 in Huntington’s Disease: Rationale and Current Status
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Huntington’s disease (HD) is an autosomal dominant hereditary disease caused by a trinucleotide repeat mutation in the huntingtin gene that results in an increased number of glutamine residues in the N terminus of huntingtin protein. Mutant huntingtin leads to progressive impairment of motor function, cognitive dysfunction, and neuropsychiatric disturbance. There are no disease-modifying treatments available. During the past decade, sirtuin-1 (SIRT1) has been the focus of intense investigation and discussion because it regulates longevity in multiple organisms and has shown beneficial effects in a variety of models of neurodegenerative disorders. Studies in different animal models provide convincing evidence that SIRT1 protects neurons in mouse models of HD as well as in Caenorhabditis elegans, although controversial results were reported in a fly model. Indeed, many connections exist between the deacetylation function of SIRT1 and its role in neuroprotection. As a result, pharmacological interventions targeting SIRT1 might become promising strategies to combat HD. This review summarizes recent progress in SIRT1 research, with a focus on the specificity of this protein as a potential therapeutic target for HD, as well as existing challenges for developing SIRT1 modulators for clinical use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mammalian Sirtuins: Biological Insights and Disease Relevance
Haigis, M. C., & Sinclair, D. A. (2010) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.4.110807.092250 · Cited by 2,085
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes
Milne, J. C., Lambert, P. D., Schenk, S., Carney, D. P., Smith, J. J., Gagne, D. J., Jin, L., Boss, O., Perni, R. B., Vu, C. B., et al. (2007) · Nature · doi:10.1038/nature06261 · Cited by 1,707 · cited 2×
“These molecules, when used in multiple rodent animal studies, including high-fat-diet-induced obese mice, ob/ob mice, and Zucker fa/fa rats, were able to normalize glucose homeostasis by improvements in insulin sensitivity [77].”
BackgroundPrice, N. L., Gomes, A. P., Ling, A. J. Y., Duarte, F. V., Martin-Montalvo, A., North, B. J., Agarwal, B., Ye, L., Ramadori, G., Teodoro, J. S., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.04.003 · Cited by 1,602 · cited 1×
“Importantly, resveratrol has not improved mitochondrial function in animals lacking SIRT1, and SIRT1 plays an essential role in the ability of moderate doses of resveratrol to activate AMPK and improve mitochondrial function [75].”
BackgroundMammalian sirtuins—emerging roles in physiology, aging, and calorie restriction
Haigis, M. C., & Guarente, L. P. (2006) · Genes & Development · doi:10.1101/gad.1467506 · Cited by 1,295 · cited 1×
“Calorie restriction increases mitochondrial biogenesis by inducing endothelial nitric oxide synthase (eNOS), and nitric oxide (NO) can activate the sirtuin 1 (SIRT1) gene [23, 24] which is the mammalian ortholog of yeast Sir2, and a highly conserved NAD-dependent protein deacetylase.”
BackgroundCalorie restriction promotes mitochondrial biogenesis by inducing the expression of eNOS
Nisoli, E., Tonello, C., Cardile, A., Cozzi, V., Bracale, R., Tedesco, L., Falcone, S., Valerio, A., Cantoni, O., Clementi, E., et al. (2005) · Science · doi:10.1126/science.1117728 · Cited by 1,107 · cited 1×
“Calorie restriction increases mitochondrial biogenesis by inducing endothelial nitric oxide synthase (eNOS), and nitric oxide (NO) can activate the sirtuin 1 (SIRT1) gene [23, 24] which is the mammalian ortholog of yeast Sir2, and a highly conserved NAD-dependent protein deacetylase.”
BackgroundKim, D., Nguyen, M. D., Dobbin, M. M., Fischer, A., Sananbenesi, F., Rodgers, J. T., Delalle, I., Baur, J. A., Sui, G., Armour, S. M., et al. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601758 · Cited by 1,074
Increased Nuclear NAD Biosynthesis and SIRT1 Activation Prevent Axonal Degeneration
Araki, T., Sasaki, Y., & Milbrandt, J. (2004) · Science · doi:10.1126/science.1098014 · Cited by 1,060 · cited 1×
“(wlds) [42], Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), Parkinson’s disease (PD), and HD [43–50], suggesting that the modulation of SIRT1 activity might be”
BackgroundCui, L., Jeong, H., Borovecki, F., Parkhurst, C. N., Tanese, N., & Krainc, D. (2006) · Cell · doi:10.1016/j.cell.2006.09.015 · Cited by 1,012
SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1
Pacholec, M., Bleasdale, J. E., Chrunyk, B., Cunningham, D., Flynn, D., Garofalo, R. S., Griffith, D., Griffor, M., Loulakis, P., Pabst, B., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.088682 · Cited by 915 · cited 1×
“These results cast doubts on the specificity of these molecules, and whether their pharmacological action might be ascribed to one or more of their demonstrated offtarget activities [78].”
BackgroundMitochondrial defect in Huntington's disease caudate nucleus
Gu, M., Gash, M. T., Mann, V. M., Javoy‐Agid, F., Cooper, J. M., & Schapira, A. H. V. (1996) · Annals of Neurology · doi:10.1002/ana.410390317 · Cited by 758 · cited 1×
“Our previous study showed that calorie restriction could ameliorate the motor phenotype and extend survival of N171-82Q HD mice [7], indicating that pathways related to energy metabolism can modify disease progression in HD.”
Background
Cited by
Resveratrol (RV): A pharmacological review and call for further research
Zhang, L.-X., Li, C.-X., Kakar, M. U., Khan, M. S., Wu, P.-F., Amir, R. M., Dai, D.-F., Naveed, M., Li, Q.-Y., Saeed, M., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112164 · Cited by 546
Sirtuins and Their Roles in Brain Aging and Neurodegenerative Disorders
Jęśko, H., Wencel, P., Strosznajder, R. P., & Strosznajder, J. B. (2017) · Neurochemical Research · doi:10.1007/s11064-016-2110-y · Cited by 259
Kumar, V., Kundu, S., Singh, A., & Singh, S. (2022) · Current Neuropharmacology · doi:10.2174/1570159x19666210609160017 · Cited by 210
Novel Role of the SIRT1 in Endocrine and Metabolic Diseases
Lu, C., Zhao, H., Liu, Y., Yang, Z., Yao, H., Liu, T., Gou, T., Wang, L., Zhang, J., Tian, Y., et al. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.78654 · Cited by 160
“SRT2183, a selective SIRT1 activator, can bind to SIRT1 enzym-peptide substrate complex, reduces the Michaelis constant for acetylated substrates, and directly activates SIRT1 through allosteric mechanism [181, 201].”
Mangiferin Protects Retinal Ganglion Cells in Ischemic Mouse Retina via SIRT1
Kim, S.-J., Sung, M.-S., Heo, H., Lee, J.-H., & Park, S.-W. (2016) · Current Eye Research · doi:10.3109/02713683.2015.1050736 · Cited by 33
Metadata
- Authors
- Duan, W.
- Venue
- CNS Drugs
- Published
- 2013-04-03
- Volume
- 27
- Issue
- 5
- Pages
- 345-352
- ISSN
- 1172-7047 (ISSN-L)
- 1179-1934
- OpenAlex
- W2164627879
- Cited by
- 53
- References
- 22
- FWCI
- 1.31
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting Sirtuin-1 in Huntington’s Disease: Rationale and Current Status. https://app.cochat.ai/papers/10.1007/s40263-013-0055-0
- The paper
- Duan, W. (2013). Targeting Sirtuin-1 in Huntington’s Disease: Rationale and Current Status. CNS Drugs. https://doi.org/10.1007/s40263-013-0055-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.